Table 2.
Content of physicians' discussion about HPV vaccine with male patients and their parents.
| |
Strongly emphasize |
Somewhat emphasize |
Discuss only if questioned |
Do not discuss |
Don't know/not sure |
|---|---|---|---|---|---|
| Content area | n (%) | n (%) | n (%) | n (%) | n (%) |
| Sexually transmitted infection prevention | |||||
| Prevention of genital warts in the patient himself | 194 (54.6) | 76 (21.4) | 40 (11.3) | 31 (8.7) | 4 (1.1) |
| Prevention of genital warts in sexual partners | 146 (41.1) | 95 (26.8) | 64 (18.0) | 37 (10.4) | 2 (0.6) |
| Cancer prevention | |||||
| Prevention of cervical cancer in female sexual partners | 201 (56.6) | 72 (20.3) | 37 (10.4) | 32 (9.0) | 2 (0.6) |
| Prevention of anal cancer in the patient himself | 114 (32.1) | 63 (17.7) | 80 (22.5) | 85 (23.9) | 4 (1.1) |
| Possible prevention of penile cancer | 113 (31.8) | 86 (24.2) | 56 (15.8) | 85 (23.9) | 3 (0.8) |
| Safety of the vaccine in males | 158 (44.5) | 85 (23.9) | 66 (18.6) | 31 (8.7) | 5 (1.4) |
| Efficacy of the vaccine in males | 141 (39.7) | 88 (24.8) | 73 (20.6) | 31 (8.7) | 9 (2.5) |
| Importance of vaccination prior to the onset of sexual activity (for patients who have not initiated sexual activity) | 215 (60.6) | 59 (16.6) | 35 (9.9) | 33 (9.3) | 4 (1.1) |
Note. Percentages account for missing data. Missing data for each item ranged from 9 to 13 participants.